Download Therapy Biomedical - International Academy of Homotoxicology

d 2.00 • US $ 2.00 • CAN $ 3.00
Biomedical
Therapy
J o urnal o f
Volume 1, Number 2 ) 2007
Integrating Homeopathy
and Conventional Medicine
Detoxification
and Drainage
• Functiotropic and Organotropic Therapy • Are You Getting the Patients You Deserve?
)
Contents
I n Fo c u s
Management of Chronic Toxin Accumulation . . . . . . . . . . . . . 4
W h a t E l s e I s N e w ? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Practical Protocols
Detoxification and Drainage . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Re s e a r c h H i g h l i g h t s
Obesity’s Helper in Triggering Diabetes . . . . . . . . . . . . . . . . .13
Around the Globe
Spain: Homotoxicology in “Flamenco Country” . . . . . . . . . . .14
Around the Globe
New E-learning Course on Homotoxicology . . . . . . . . . . . . . . 15
Re f r e s h Yo u r H o m o t ox i c o l o g y
Synergy Between Functiotropic
and Organotropic Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 6
M a r ke t i n g Yo u r P r a c t i c e
Marketing to Target Groups –
Are You Getting the Patients You Deserve? . . . . . . . . . . . . . . .18
Specialized Applications
Detoxification of Patients
in the Dedifferentiation Phase . . . . . . . . . . . . . . . . . . . . . . . .20
Making of ...
Manufacturing Liquid Medications:
How Do Those Drops Get Into the Bottle? . . . . . . . . . . . . . . .22
Cover photograph
© Titus Lacoste/Riser/Getty Images
)
2
C r o s s w o r d P u z z l e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24
Published by/Verlegt durch: International Academy for Homotoxicology GmbH, Bahnackerstraße 16,
76532 Baden-Baden, Germany, e-mail: [email protected]
Editor in charge/verantwortlicher Redakteur: Dr. Alta A. Smit
Print/Druck: Konkordia GmbH, Eisenbahnstraße 31, 77815 Bühl, Germany
© 2007 International Academy for Homotoxicology GmbH, Baden-Baden, Germany
)
Detoxification Is Finally
Getting a Hearing
Dr. Alta A. Smit
D
etoxification and drainage are
one of the pillars of antihomotoxic treatment. Detox medications
are administered routinely by practitioners of homotoxicology, but in
other branches of medicine, toxin
accumulation (except in the form of
drug overdose) is not always seen as
a problem until it becomes lifethreatening. Because chronic intoxication is insidious and damage on
the molecular level occurs over years,
the role of chronic intoxication has
been largely ignored.
As the introduction of new substances into the environment increases and as the proponents of
global warming theory are finally
getting a hearing, we see increasing
awareness of the effects human beings may have on the planet and
themselves. The picture that nature
reflects back at us can be sobering,
as we see from the banning of DDT
after the publication of Rachel Carson’s Silent Spring.1
Now evidence of the chronic effects
of toxins is mounting in reputable
journals: Science has published observations of genetic damage that is
seen only in the next generation,
The New Scientist reported on the effects of persistent organic pesticides
(see summary on page 13 of this
journal), and many articles have appeared on endocrine disruption and
the genetic effects of many toxins.2-4
Data released at a conference in Edinburgh on the 10th of September
this year confirmed that both passive and active smokers suffer fewer
heart attacks when smoking is
banned in public places, confirming
that legislation can indeed have an
effect on environmental safety.5
However, till we humans can maintain a balance between our industry
and our own health, the only thing
patients and practitioners can do is
to support the elimination of toxins
from the body. That is why this issue
is devoted to this very important
topic. Our focus article examines the
effects of chronic intoxication, while
practitioners share their experiences
with detoxification in various types
of patients. In our new column Marketing Your Practice, you will learn
about target-group oriented marketing, and the Making of… series will
introduce you to the process of
manufacturing liquid medications.
Last but not least, Around the globe
will take you on a journey to Spain.
Alta A. Smit, MD
References:
1. Carson R. Silent Spring. Boston, MA:
Houghton Mifflin, 1962.
2. Anway MD, Cupp AS, Uzumcu M,
Skin­ner MK. Epigenetic transgenera­
tional actions of endocrine disrup­
tors and male fertility. Science 2005;
308(5727):1466-1469.
3. Welshons WV, Thayer KA, Judy BM,
Taylor JA, Curran EM, vom Saal FS. Large
effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ
Health Perspect 2003;111(8):994-1006.
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
4. Hartwig A, Asmuss M, Ehleben I, Herzer U, Kostelac D, Pelzer A, Schwerdtle
T, Bürkle A. Interference by toxic metal
ions with DNA repair processes and cell
cycle control: molecular mechanisms.
Environ Health Perspect 2002;110(Suppl
5):797-799.
5. Cramb A. Scottish smoking ban cuts
heart attacks. Telegraph. 12 September,
2007. http://www.telegraph.co.uk/
news/main.jhtml?xml=/news/2007/
09/11/nsmoking111.xml. Accessed
No­vem­ber 19, 2007.
)
3
) I n Fo c u s
Management of
Chronic Toxin Accumulation
)
4
By Luigi Piroli, MD
Introduction
in areas where the chemicals were
never used. Bioaccumulation of
these compounds causes disease in
living beings. In humans, the immune, endocrine, and neurological
sys­tems are the most affected.3
Xenobiotics and/or individual inability to deal with them seem to be
at the root of many modern diseases,
including Parkinson’s disease, chro­
nic fatigue syndrome, and cancer.4-6
Modern medicine is quite successful
in diagnosing and treating acute intoxications as medical emergencies
(heavy metal accumulation, drug
poisoning, etc.) as well as various
sub-acute, symptomatic toxicities
(chemicals, drugs, and/or other xe­
no­biotics), but only if laboratory
evidence of intoxication is found. In
recent years, however, the burden of
chronic toxin accumulation has become clearer and more disturbing as
the effects of minute doses of toxins
over time and effects on subsequent
generations become evident.1,2
Individual tolerance of or susceptibility to specific toxins may vary. A
biological system’s tolerance of a
toxin is partly genetic and partly acquired on the basis of enzymatic induction and/or inhibitions, the degree of functionality of the target
organ, and functional reserve capacity of specific organ systems. The
clinical manifestations of biological
effects of toxins depend not only on
the physical and chemical properties
of the toxin itself but also on the duration and route of exposure, the
toxin’s mechanism of action, and
(obviously) on individual susceptibility. Modern laboratories can now
test for individual susceptibility.
Chemical compounds, which comprise the bulk of environmental toxins, have spread throughout the
world via the ground water, rain,
and winds, and are now present even
Managing chronic toxin
accumulation
As is clear from the above, in assessing a patient with toxicity, multiple
factors need to be taken into account, including not only the total
toxin load but also the individual
patient’s response. Two patients exposed to the same amount of the
same toxin may respond differently.
Individual differences are apparent
not only in how patients deal with
toxins (primarily differences in metabolism or biotransformation) but
also in how the toxins are stored
and eliminated. Rather than assessing total exposure, therefore, it is
more important to assess what each
patient is doing with the toxin load.
In homotoxicology, this is assessed
indirectly on the Disease Evolution
Table, where we measure the pa­
tient’s regulatory ability in terms of
disturbance in homeostasis.7
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
Biotransformation
or metabolization of toxins
Substances may undergo processes
that make them water-soluble and
thus more readily excreted, or they
may undergo bioinactivation, which
reduces the toxicity of the end product. Biotransformation takes place
primarily in the liver and the intestinal tract and to a lesser extent in the
skin, kidneys, and other organs.
Phase I and II reactions
These have been described elsewhere and will not be discussed in
depth here.8 Suffice it to say that
phase I involves oxygenation; in
pha­se II, conjugation adds a watersoluble group to the reactive site
formed in phase I. Thus detoxification is not a single process but a
number of processes involved in
the biotransfomation of xenobiotics.
Eve­ry step depends on several cofactors such as vitamins and minerals. Because phase I enzymes are
mixed-function oxidases, a number
of free radicals are formed during
the detoxification process, so it is
important to provide adequate nutritional and antioxidant support for
the patient.
) I n Fo c u s
Phase III –
The antiporter system
This system is active primarily in the
intestines. Paradoxically, the intestinal mucosa functions both as a barrier and as a filter. As the first point
of contact with drugs and food as
well as environmental xenobiotics,
the mucosa has developed a complex set of defense mechanisms, one
of which is the so-called antiporter
system. In this process, xenobiotics
are actively pumped out of the cell
to reduce their intracellular concentrations. This phenomenon was first
observed in cancer cells, which
actively eliminate chemotherapy
agents. Antiporter activity in the intestinal wall seems to be co-regulated with the phase I CYP3A4 enzyme.9 It is therefore important to
use products such as Mucosa compositum to support the intestinal
wall during any detoxification and
drainage treatment.
Storage and elimination
of toxins
Release of toxins from their reservoirs depends on toxicokinetics (to­
xins are cleared “upstream” first, i.e.,
out of the blood stream), on whether
the reservoir is a rapid or slow exchange system, and on whether the
chronobiology of the tissue (e.g., the
matrix) is intact.8 Adipose tissue, a
major reservoir of fat-soluble toxins,
is a slow exchange system, as is
bone. Consequently, obese patients
may have a higher toxic load. When
one or more factors will affect the
release of toxins, drainage should be
stimulated long enough to ensure
clearance of the tissue in question
(see below). A patient’s total toxic
load thus depends on the exposure
and storage on the one hand and on
biotransformation and elimination
on the other.
Measurement of toxin
accumulation and the
ability to biotransform
toxins
One of the major obstacles facing a
physician is how to assess each patient’s current toxic load and exposure risk. It is well known in biological medicine that individuals
respond differently to the same exposure – a fact that makes the physician’s task even more daunting.
Since intoxication may produce no
symptoms, researchers are now
hunting for biomarkers to aid in assessing toxin accumulation and the
effect of the toxin on individuals
and especially in identifying individuals at risk for the effects of certain exposures.10
For practical purposes, testing methods can be divided into four
groups:
1. Testing for the presence
of toxins
2. Assessing the body’s ability
to biotransform toxins and to
protect itself from their effects
3. Assessing individualized risk
4. Assessing toxicity indirectly,
through symptoms
1. Testing for the presence
of toxins
In recent years, more sophisticated
biomarkers have supplanted the
commonly used fat aspiration biopsy. Fat biopsy is an invasive procedure that ultimately provides information only on the accumulation of
fat-soluble toxins; it says nothing
about how the toxin interacts with
and impacts the tissue. Biomarkers
of toxin exposure may be either exogenous substances or their metabolites or products of the interaction
of the xenobiotics with target molecules or cells within a compartment
of the body, e.g., adducts with DNA
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
or red blood cells. Many of the assays are highly sophisticated and
beyond the scope of this article,
since they are not routinely used in
practice but rather for research purposes and epidemiological studies
of exposures.10
Testing for toxic metals can also be
done via hair analysis or urinary
testing after provocation with
DMSA, as these compounds are
largely undetected by normal laboratory analyses. Serum testing, however, may be used for lead, mercury,
aluminum, and cadmium.9
2. Assessing the body’s ability
to biotransform toxins and to
protect itself from their effects
2.1 Urinary metabolic profile
Biomarkers commonly used in practice include the so-called urinary organic acids. Originally used to detect inborn errors of metabolism,
these tests now are a useful tool in
the assessment of chronic diseases.
Organic profiling can be used not
only to detect biomarkers of toxicity
but also to assess central energy
pathway intermediates, carbohydrate metabolism, specific vitamin
deficiency indicators, neurotransmitter metabolism, and the products of
the intestinal flora. Where available,
it offers a comprehensive way to assess the patient’s individual response
from a genetic and environmental
perspective and indicates which cofactors should be replaced to ensure
optimum detoxification.11
Direct markers of toxicity include
glucarate, a by-product of phase II
detoxification. Decreased glucarate
indicates reduced overall hepatic
function, whereas elevated glucarate
indicates enzyme induction. For example, glucarate is elevated in pa­
tients exposed to pesticides. Elevat­
ed orotate is a sensitive test of both
ammonia build-up and arginine
)
5
) I n Fo c u s
availability. 2-methylhippurate, a
metabolite of the common solvent
xylene, is used to monitor xylene
exposure; pyroglutamate measures
glutathione metabolism and sulfate
measures sulfatation pathways.
When the sulfate-creatinine ratio is
low, the sulfur containing phase II
pathways need replenishment (glutathione, cysteine, taurine).
2.2 Challenge testing
Standard liver and kidney function
tests reveal only pathologies, not
metabolic integrity. In contrast, challenge tests may measure not merely
liver integrity, for example, but the
function of all organs involved in
metabolizing the substance in question, such as the kidneys and P450
in the skin as well. The most common of these probe tests is the caffeine clearance test, which assesses
the integrity of CYP1A2 activity. In
this challenge test, a specified
amount of caffeine is ingested, after
which two or three saliva samples
are measured at specific times. Because caffeine is almost completely
absorbed in the intestine, its clearance rate reflects the metabolic activity of the P450 enzymes. Other
probes are available for specific
P450 enzymes, e.g., erythromycin
(breath test) to measure CYP3A4
activity.
)
6
3. Measuring individual
susceptibility
There is increasing interest in the
role human genome variations play
in modifying the effect of environmental health hazards, rendering
some individuals or groups more
susceptible to post-exposure development of disease.12 More than 99
percent of human DNA is identical
in all individuals, yet the less than
one percent of DNA that differs
from person to person ensures that
no two humans (other than identical
twins) are exactly alike. To create all
the cells and tissues in the body,
DNA must replicate itself billions
and trillions of times, creating numerous opportunities for errors. The
most common error is called a single
nucleotide polymorphism or SNP
(pronounced “snip”), in which a single nucleotide in a gene is changed.
SNPs in a gene may increase – or
more commonly, decrease – the activity of detoxifying enzymes, either
of which can be harmful. For instance, CYP1B1 is responsible for
4-hydroxylation of estrogen and activation of polycyclic aromatic hydrocarbons (which occur, for example, in cigarette smoke, car exhaust,
and charbroiled foods). Thus activation of this enzyme produces oxidative stress and 4-hydroxyestrogens,
which cause DNA damage in breast
tissue. Other SNPs have been associated with lower 2:16-hydroxy­
estrone ratios and increased risk of
breast cancer, especially with concomitant xenobiotics exposure and
accumulation.
Test panels for SNPs involved in
detoxification are now available
through selected laboratories. Genetic testing, once of only theoretical interest for the future, is increasingly becoming part of our quest to
individualize patient treatment and
to assess risk. Of course this gives
new meaning to the famous words
of Claude Bernard, who said that
the bacterium is nothing, but the
terrain is everything! Tests for SNPs
related to detoxification enzymes assess the terrain the toxin will encounter, thus the predisposition of
the patient to be affected by the
toxin.
4. Indirect assessment through
symptoms
This method, although the least
specific, offers an inexpensive, practical means of following patients
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
with toxicity. Here, the constellation
and severity of symptoms play a
role, so a simple questionnaire* is
administered and then repeated every time the patient comes for a
follow-up. In effect, the patient
serves as his or her own control from
baseline. Movement of symptoms
can also be used as a diagnostic predictor, as symptoms tend to move
from deeper to more superficial organs and from the deposition phase
to the excretion phase as toxins
are eliminated and the patient improves.
The detoxification questionnaire
is a self-administered test that includes
questions about all the major toxicity
symptoms.
Practical management of
bioaccumulated toxins
After a careful history and a thorough medical examination, the patient should be classified according
* To obtain a copy of the Detox questionnaire,
please contact your local Heel distributor.
) I n Fo c u s
to the severity of his or her illness,
using either the Disease Evolution
Table or a questionnaire. If available,
one or more specialized tests may be
added. Patients with high toxic
loads (either a point count of over
100 on the questionnaire or multiple markers in urinary metabolic
testing) and patients with specific
health problems (e.g., cancer, obesity, prior drug addiction, flare-ups of
inflammatory disease, etc.) constitute
a group that needs organotropic,
supportive treatment of the organs
of detoxification and elimination
before drainage is implemented. After six weeks of supportive treatment, the regimen shifts to functiotropic support of tissue drainage
(Detox-Kit). Patients with low toxic
exposure and mild symptoms such
as skin rashes and fatigue may begin
immediately with the functiotropic/
drainage approach (see Table 1 for
summary).
As mentioned above, it is vitally important to allow slow exchange systems to release all accumulated toxins. In patients with high toxic loads,
this may take several months. Lymphomyosot is thus added to the reg-
imen for several weeks or months to
ensure complete detoxification.
3. Crinnion WJ. Environmental medicine,
part one: the human burden of environmental toxins and their common health
effects. Altern Med Rev 2000; 5(1):
52-63.
4. Armstrong B, Hutchinson E, Unwin J,
Fletcher T. Lung cancer risk after exposure to polycyclic aromatic hydrocarbons:
A review and meta-analysis. Environ
Health Perspect 2004;112(9):970-978.
5. Brody JG, Rudel RA. Environmental pollutants and breast cancer. Environ Health
Perspect 2003;111(8):1007-1019.
6. Welshons WV, Thayer KA, Judy BM,
Taylor JA, Curran EM, vom Saal FS. Large
effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ
Health Perspect 2003;111(8):994-1006.
7. Van Brandt B. The Disease Evolution Table (DET). J Biomed Ther
2007;Spring:13-15.
8. Smit A. Practical detoxification and
drainage. J Biomed Ther 2007;Winter:11-15.
9. Liska D, Lyon M, Jones D. Detoxification and Biotransformational Imbalances. Explore 2006;2(2):122-140.
10.Watson WP, Mutti A. Role of biomarkers in monitoring exposures to chemicals: present position, future prospects.
Biomarkers 2004;9(3):211-242.
11.Pizzorno JE, Murray MT. Detoxification: a naturopathic perspective. Nat
Med J 1998;1:6-17.
12.Kelada SN, Eaton DL, Wang SS, Rothman NR, Khoury MJ. The role of
genetic polymorphisms in environmental health. Environ Health Perspect
2003;111(8):1055-1064.
Conclusion
Treatment of chronic toxin accumulation is individualized according to
the severity of the intoxication and
the patient’s regulatory status. Several tools are available to asses these
factors, but simple questionnaires
seem to be the most practical and
inexpensive choice. Advanced organotropic organ support is employed first in severe cases, followed
by the functiotropic Detox-Kit for
drainage. Use of Lymphomyosot
over weeks or months ensures drainage of slow exchange compartments
such as adipose tissue.|
References:
1. Anway MD, Cupp AS, Uzumcu M,
Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science
2005;308(5727):1466-1469.
2. Calabrese EJ, Baldwin LA. Hormesis: Ushaped dose responses and their centrality in toxicology. Trends Pharmacol Sci
2001;22(6):285-291.
Liver
Urinary tract/
Kidney
Lymph
Gall­bladder
Connective
tissue
Advanced organ support for six weeks
for patients with severe toxicity
Hepar comp.
Solidago comp.
Hepar comp.
Thyreoidea comp.
Alternative products
(if above not available)
Hepeel
Reneel
Basic detoxification and drainage for 12 weeks
Detox-Kit
Detox-Kit
Detox-Kit
ChelidoniumHomaccord
Detox-Kit
For cellular detoxification, add
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Pulsatilla comp.
Note
Cellular detoxification is best added during the advanced organ support phase, although in some cases
(e.g., inflammatory skin disease), it is not added until the basic detoxification phase. Continue with Lymphomyosot for 4-6 weeks for
patients with mild toxicity and 12 weeks for patients with severe toxicity.
Dosage
Ampoules: In general, 3-1 times weekly 1 ampoule i.m., s.c., i.d.
Drops: In general, 10 drops 3 times daily
)
Table 1:
Advanced and basic detox therapy
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
7
) What Else Is New?
Napping is no substitute
for a good night’s sleep
If another woman likes
the way he looks …
Left: Daytime napping in young
Parents should forget about daytime
naps for their children and instead
make sure the kids get to bed on
time. A recent study examined the
relationship between sleep patterns
and the behavior and intelligence of
738 children aged two to twelve.
Children who took naps during the
day had a harder time going to sleep
at night and getting up the next
morning. Other studies indicate that
due to sleep deficits, children who
nap are also more likely to be moody
in the mornings and to perform
poorly on intelligence tests. The
con­sequences are similar when children go to sleep too late, even if
they do not nap during the day. Parents are advised to be consistent
about ensuring that their children
go to bed (and go to sleep) in time
to get all the sleep they need in one
uninterrupted period of rest.
That women and men think differently was known long before the
publication of books such as Men are
from Mars, Women are from Venus or
Why Men Don’t Listen and Women
Can’t Read Maps. Many studies have
confirmed that the genders process
emotional events and logical sequences differently. A new study
now illustrates gender differences in
behavior as well. In this study, men
and women were asked to rate the
attractiveness of men in photos. The
researchers showed the viewers pairs
of male faces with the profile of a
woman between them. In some cases, the woman was smiling; in others
she was not. If the woman appeared
to be smiling at one man, female
viewers also tended to find him the
to their peers who only sleep at night.
children may be linked to poorer sleep
and mental functioning in comparison
Right: Women will prefer the men that
other women find attractive.
more attractive of the two, whereas
male viewers rated him as the less
attractive. The authors concluded
that women judge a man’s attractiveness according to how other
women react to him. By contrast,
men react negatively to men whom
women consider attractive – a fact
the researchers associated with the
competitive character of male thinking.
Proceedings of the Royal Society
2007;274(1611):899-903
New Scientist June 30, 2007;(2610):14
F O R P RO F E S S I ONA L U S E ON LY
)
8
The information contained in this journal is meant for professional use only, is meant to convey general and/or specific worldwide scientific information relating to the
products or ingredients referred to for informational purposes only, is not intended to be a recommendation with respect to the use of or benefits derived from the
products and/or ingredients (which may be different depending on the regulatory environment in your country), and is not intended to diagnose any illness, nor is it
intended to replace competent medical advice and practice. IAH or anyone connected to, or participating in this publication does not accept nor will it be liable
for any medical or legal responsibility for the reliance upon or the misinterpretation or misuse of the scientific, informational and educational content of the
articles in this journal.
The purpose of the Journal of Biomedical Therapy is to share worldwide scientific information about successful protocols from orthodox and complementary practitioners. The intent of the scientific information contained in this journal is not to “dispense recipes” but to provide practitioners with “practice information” for a better
understanding of the possibilities and limits of complementary and integrative therapies.
Some of the products referred to in articles may not be available in all countries in which the journal is made available, with the formulation described in any article or
available for sale with the conditions of use and/or claims indicated in the articles. It is the practitioner’s responsibility to use this information as applicable
and in a manner that is permitted in his or her respective jurisdiction based on the applicable regulatory environment. We encourage our readers to share
their complementary therapies, as the purpose of the Journal of Biomedical Therapy is to join together like-minded practitioners from around the globe.
Written permission is required to reproduce any of the enclosed material. The articles contained herein are not independently verified for accuracy or truth. They have
been provided to the Journal of Biomedical Therapy by the author and represent the thoughts, views and opinions of the article’s author.
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
) What Else Is New?
Pedestrians chatting on a cell phone in
street traffic pose a significantly higher
risk to both themselves and others
than either iPod users or ordinary
pedestrians.
What to do when
your avatar is sick?
Alternative treatment for
apes, snakes, and elephants
Cell phones
distract pedestrians
Since 2003, an artificial world has
been in the making on the online
platform “Second Life” (www.sec­
ondlife.com). This imaginary world
promises its inhabitants, called avatars, a life in paradise. Each user has
the opportunity to create his or her
own avatar as a virtual alter ego.
Avatars are usually attractive, rich,
and successful. They acquire property, build houses, and buy and sell
with virtual money. They can also
take advantage of medical services.
Recently, the first German-speaking
medical practice opened in “Second
Life,” offering office hours for one
hour each week. A virtual nurse
ca­res for patients in the practice.
Mental health patients can seek
treatment in the clinic of an Australian psychiatrist. Health services
such as Ann Myers Medical Center
or the New Babbage Medical League
provide information and tips about
health issues, and eight national Institutes of Health are registered. Of
course, there is no way to tell whether real medical professionals stand
behind the virtual offerings.
Increasingly, sick animals in the Singapore Zoo are being treated (and
cured) with alternative therapies instead of conventional medicine.
Chinese herbal mixtures often help
when classical medicine fails. For
example, phytotherapy was used to
cure an orangutan’s digestive problems and a snake’s chronically swollen snout, and acupuncture was successful in treating a limping female
elephant. The zoo’s head veterinarian emphasizes that he uses Western
medicine first but is having increasingly frequent success with alternative medicine.
Ärztezeitung April 17, 2007
The results of a recent study may
mark the beginning of hard times
for cell phone users. The researchers
concluded that pedestrians using
cell phones in street traffic posed a
greater danger to themselves and
the general public than either iPod
users or ordinary pedestrians. The
scientists chose a common, everyday
situation for their investigation:
They observed how many individuals attempted to cross a street without first checking for oncoming vehicles. Almost half (48 percent) of
the cell phone users were so engrossed in their conversations that
they attempted to cross the street
without checking for traffic. This
behavior was observed in only 16
percent of the iPod users among
participants in the study. Surprisingly, 25 percent of the ordinary pedestrians who made up the control
group also attempted to cross without first checking for traffic.
Possible fallout from this study
might include future restrictions on
cell phone use by pedestrians on
public streets or loss of insurance
coverage for cell phone users who
cause accidents.
When conventional medicine fails,
New Scientist June 2,
2007;(2606):19|
Ärztezeitung May 21, 2007
veterinarians of the Singapore Zoo
resort to alternative therapies such as
Chinese herbal mixtures.
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
)
9
) Practical Protocols
Detoxification and Drainage
Eliminating toxins from the body
By Bruce H. Shelton, MD, MD(h), DiHom
There are very few patients who don’t need detoxification
and drainage intervention at all. Furthermore, each patient’s
status is unique, so in designing a treatment plan, it is
im­portant to strike a balance between the patient’s previous
ex­posure (toxic load) and the organism’s ability to detoxify
(regulation ability).
F
)
10
or this purpose, patients are
gene­rally divided into two
groups. Group 1 includes patients
with mild to moderate toxicity. In
general, these are patients with mild
symptoms and exposure. They elect
to do a general cleansing or have
milder diseases such as headaches,
acne, etc. Group 2 includes patients
with severe toxicity (known exposure) as well as patients with severe
diseases such as cancer, autoimmune
diseases, etc. These patients’ regulation ability is reduced. Group 2 also
includes former drug addicts as well
as patients who have received chemotherapy.
Due to their advanced toxicity,
group 2 patients need advanced supportive detoxification that prepares
the organs of detoxification and
elimination for the drainage phase
(accomplished primarily through
Lymphomyosot, a component of the
Detox-Kit). The advanced organ
support is thus more organotropic in
character, whereas the basic detoxi-
fication and drainage is more functiotropic. In general, advanced organ
support is administered for six
weeks, followed by use of the Detox-Kit. In most cases, tissues will
still need to be drained of residual
toxins, so the use of Lymphomyosot
alone is advised for several months
longer (for protocols, see BT Winter
2007).
Special case 1: Patients
with inflammatory skin disease,
such as eczema or psoriasis
The skin, classically called the “mirror of the soul,” is also a mirror of
the liver and the gut. In cases of skin
disease, it is essential to remember
that the P450-containing system in
the skin is the same as that in the
liver and in the gut. Psoriasis patients in particular need bowel
cleansing, which should be part of
the initial advanced organ support.
Thus Mucosa compositum and Cutis
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
compositum play a special role in
these patients, although functiotropic medications such as Nux vomica-Homaccord, Berberis-Homaccord, and Lymphomyosot, along
with Hepeel, are the mainstays in
the treatment of skin disease.
Patients with inflammatory skin disease are at high risk of flare-ups if
toxin drainage is initiated before the
liver and gut are ready to cope with
the load. These patients need to be
treated with care even though they
may not seem very ill. In some cases,
flare-ups will simply mean that patients need higher doses of cortisone, but in other cases hospitalization may become necessary if skin
sloughing is severe.
Patients with eczema are in a Th2
rigidity state, so they should first
undergo several weeks of initial immunomodulation to get the disease
under control, followed by advanced
organ support, before the drainage
period is initiated. Engystol is the
medication of choice together with
the appropriate suis-organ preparation, in this case Cutis compositum.
By contrast, patients with psoriasis
are in a Th1 state, so they should be
treated with Traumeel oral ampoules
and Cutis compositum. In both cases, it is preferable to add the catalysts during the drainage phase rather than during advanced organ
support (see protocol in Table 1).
) Practical Protocols
Psoriatic plaques are areas of inflammation
and excessive skin production. They frequently occur on the skin of the elbows and knees.
Disease-specific treatment
For Th1 rigidity: Traumeel and Cutis compositum
For Th2 rigidity: Engystol and Cutis compositum
Schwef-Heel
Weeks 1-4 (or even longer in severe cases)
Liver
Urinary tract/
Kidney
Lymph
Advanced organ support
Skin
Gut
Cutis comp.
Mucosa comp.
Note
Due to the high incidence of leaky gut in inflammatory skin diseases, initial treatment of the gut and immune system is
paramount. The suis organs induce Th3 cells, and thus immunetolerance to the corresponding organs.
Dosage
Ampoules: In general, 3-1 times weekly 1 ampoule i.m., s.c., i.d.
Connective
tissue
Drops: In general, 10 drops 3 times daily
Advanced organ support
Duration: 6 weeks
Liver
Urinary tract/
Kidney
Advanced organ support
Hepar comp.
Solidago comp.
Alternative products
(if above not available)
Hepeel
Reneel
Liver
Basic detoxification and drainage
For cellular detoxification, add
Lymph
Skin
Gut
Connective
tissue
Cutis comp.
Mucosa comp.
Thyreoidea comp.
Galium-Heel/
Lymphomyosot
Schwef-Heel
Nux vomicaHomaccord
Pulsatilla comp.
Urinary tract/
Kidney
Lymph
Skin
Gut
Connective
tissue
Detox-Kit
Detox-Kit
Detox-Kit
Detox-Kit
Detox-Kit
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Basic detoxification and drainage
Coenzyme comp./
Ubichinon comp.
Note
Because Schwef-Heel is a potency chord, it does not cause aggravation to the extent classically ascribed to sulfur-containing medications.
Adjuvant use of probiotics throughout the treatment should be considered.
Dosage
Ampoules: In general, 3-1 times weekly 1 ampoule i.m., s.c., i.d.
Drops: In general, 10 drops 3 times daily
)
Table 1:
Protocol for inflammatory skin disease
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
11
) Practical Protocols
Chronic fatigue syndrome is a complex
and highly debilitating disorder
characterized by chronic mental and
© Stockbyte/Getty Images
physical exhaustion. It occurs more
often, but not exclusively, in women.
Special case 2: Patients
with chronic fatigue syndrome
to the onset of the syndrome. Due to
general immune imbalance (Th2 rigidity) and mitochondrial impairment in these patients, advanced organ support is essential, but even
before that, support for the mucous
membranes, the immune system, and
the neuroendocrine system is helpful. This is best done with a combi-
All patients with chronic fatigue
syndrome have some form of toxicity. Some of these patients present
primarily with symptoms of intoxication and have a history of toxic
exposure, often temporally related
Disease-specific treatment
nation of Mucosa compositum and
Tonsilla compositum. After two
weeks, advanced organ support can
begin, followed by the drainage
phase. If relapse occurs during the
drainage phase, advanced organ support should be resumed for at least
another six weeks (see protocol in
Table 2).|
Aletris-Heel
Followed by detoxification therapy:
Liver
Urinary tract/
Kidney
Weeks 1-2
Lymph
Gut
Tonsilla comp.
Mucosa comp.
Weeks 3-8:
Advanced organ support
Hepar comp.
Solidago comp.
Tonsilla comp.
Alternative products
(if above not available)
Hepeel
Reneel
Galium-Heel
Nux vomica-Homaccord
Pulsatilla comp.
Weeks 9-20:
Basic detoxification and drainage
Detox-Kit
Detox-Kit
Detox-Kit
Detox-Kit
Detox-Kit
For cellular detoxification, add
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Thyreoidea comp.
Note
These patients need very gradual treatment. Because they often have multiple chemical sensitivities, it is advisable to first restore the integrity
of the gut lining while administering Tonsilla comp. to support the adrenals and the hypothalamus. This also supports the immune system.
Dosage
Ampoules: In general, 3-1 times weekly 1 ampoule i.m., s.c., i.d. Drops: In general, 10 drops 3 times daily
Table 2:
Protocol for chronic fatigue syndrome
)
Connective
tissue
12
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
) Re s e a r c h H i g h l i g h t s
Obesity’s Helper in Triggering Diabetes
The role of POPs in the pathogenesis
of type 2 diabetes mellitus
By Catherine E. Creeger
I
stasis model assessment (HOMA)
method.4 The authors selected 19
POPs detected in at least 60% of
study subjects and then examined
associations of POPs and HOMA of
insulin resistance (HOMA-IR) within 5 POP subclasses.
n 2006, an international team of
researchers analyzed a data subset
of the U.S. National Health and
Nutrition Examination Survey
(NHANES) and discovered striking
dose-response relations between serum concentrations of persistent organic pollutants (POPs) and pre­
valence of diabetes.1 NHANES,
con­ducted by the U.S. Centers for
Disease Control and Prevention,
was designed to be nationally representative of the non-institutionalized U.S. civilian population. This
first study revealed strong associations between both organochlorine
(OC) pesticides and nondioxin-like
polychlorinated biphenyls (PCBs)
and diabetes. Moreover, the prevalence of diabetes was quite low
among subjects with high BMIs but
low serum concentrations of POPs.1
POPs stored in adipose tissue may
therefore play a considerable role in
the pathogenesis of diabetes.2,3
Objective
In a recently published subsequent
study, the team of authors reviewed
the same dataset to investigate POPs
and insulin resistance (a frequent
precursor of type 2 diabetes) in nondiabetic subjects.
Research design and methods
The NHANES surveys included data
on serum concentrations of various
biologically important POPs or
their metabolites and estimated
insulin resistance using the homeo-
Results
The sample of 749 participants included 46.3% males and 49.7%
Caucasians. Mean age was 48.2 ±
18.9 years. Among 5 subclasses of
POPs, only OC pesticides correlated
strongly with HOMA-IR in these
non-diabetic subjects, although specific individual nondioxin-like PCBs
were also associated with higher
HOMA-IR values. The findings suggest that chlordane (an agricultural
pesticide banned in the US since the
1980s) may be the most important
POP involved in the pathogenesis
of type 2 diabetes by influencing insulin resistance, although there has
been no experimental study on the
possible biological mechanism(s).
Conclusions
The present study found serum concentrations of OC pesticides to be
strongly and positively associated
with insulin resistance among nondiabetic subjects. Coupled with the
previous study’s findings on associations between POPs and diabetes,
the current results suggest that background environmental exposure to
some POPs, especially OC pesti­ci­des, may be critically involved in
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
the pathogenesis of diabetes through
a pathway involving insulin resistance. In the POP subclass of OC
pesticides and their metabolites,
oxychlordane (a chlordane metabolite) and trans-nonachlor (a chlordane impurity) were most strongly
associated with insulin resistance in
non-diabetic subjects. The interaction be­tween OC pesticides and
obesity on the risk of both insulin
resistance and diabetes suggests that
POPs stored in adipose tissue may
play a role in the current epidemic
of type 2 diabetes.|
(Excerpted from: Lee DH, Lee IK, Jin
SH, Steffes M, Jacobs DR. Association between serum concentrations
of persistent organic pollutants and
insulin resistance among nondiabetic adults. Diabetes Care 2007;
30(3):622-628.)
References:
1. Lee DH, Lee IK, Song KE, Steffes M, Toscano W, Baker BA, Jacobs DR Jr. A strong doseresponse relation between serum concentrations of persistent organic pollutants and
diabetes: results from the National Health
and Examination Survey. Diabetes Care 2006;
29:1638-1644.
2. Porta M. Persistent organic pollutants and
the burden of diabetes. Lancet 2006;368:
558-559.
3. Lee DH, Jacobs DR, Porta M. Could low
level background exposure to persistent organic pollutants contribute to the social burden of type 2 diabetes? J Epidemiol Community
Health 2006;60:1006-1008.
4. Centers for Disease Control and Prevention.
Third National Report on Human Exposure to Environmental Chemicals. Atlanta, GA: CDC,
2005.
)
13
) Around the Globe
Spain:
Homotoxicology
in “Flamenco Country”
)
14
By Rüdiger Schneider, PhD
W
gram in Manual Medicine and Applied Homotoxicology. The course
of study encompasses more than
600 hours of lectures (300 hours
each of theoretical and practical
work) and awards internationally
recognized European continuing
education credits. Similar programs
emphasizing homotoxicology are
already in the planning stages at
various other universities. Workshops on homotoxicology are another means of increasing physicians’ knowledge about the use of
antihomotoxic medications in daily
medical practice.
hat is Spain, one of Europe’s
favorite vacation destinations, best known for? Bullfights,
sherry, Don Quixote, the Prado, the
Real Madrid soccer/football team…
Each year, many tourists visit Spain’s
gorgeous landscapes and bustling
cities, enjoy its national cuisine (who
can resist paella?), join in its traditional fiestas, or spend their vacations relaxing on its beaches. The
Spaniards are proud of their country, their culture, their history, and,
last but not least, their language,
noted for its rapid-fire tempo.
Homotoxicology has been established in Spain for many years. Laboratorios Heel España, S.A.U., with
its headquarters near Madrid, may
still be known to some of you under
its former name, Phinter-Heel. Its
initial offerings also included classical homeopathic medications. Meanwhile, the business has grown to
employ more than 80 people and
successfully markets antihomotoxic
medications in Spain. Heel España
has its own manufacturing facilities
and produces many Heel products
locally.
As in many other countries, the keystone of Heel España’s success is
continuing education programs and
symposia, which attract more than
200 participants per event. Through
the company’s efforts, homotoxicology is also finding a home in Spanish universities. For example, the
Universidad Complutense in Madrid
is even offering a masters-level pro-
Focus on detoxification
Detoxification is an essential component of the antihomotoxic therapeutic model. The other two pillars
of antihomotoxic therapy (cellular
activation/organ strengthening and
immunomodulation) take effect best
only after accumulated toxins have
been eliminated from the patient’s
body. Consequently, basic detoxification with the Detox-Kit (which
includes Lymphomyosot, Nux vomica-Homaccord, and Berberis-Homaccord, all in liquid form) is one of
the cornerstones of continuing education programs for physicians in
Spain. Many health-conscious Spaniards already rely on the Detox-Kit.
It is well known that Spain is crazy
for sports, especially soccer/football, so it is not surprising that homotoxicology has also found its way
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
into the country’s elite sporting
events: Heel España has succeeded
in becoming the sole sponsor of the
AEMEF, an association of the team
physicians of all 1st and 2nd league
soccer/football clubs in Spain, such
as Atlético Madrid, Real Madrid,
and FC Barcelona. Heel España
holds workshops on biopuncture for
the physicians and physiotherapists
of this association. The workshops
demonstrate the effectiveness of
suitable antihomotoxic medications
in treating sports injuries and show
practitioners that this treatment approach ensures a speedy recovery
and facilitates an early return to
sports activities. |
Heel España is the official sponsor
of the AEMEF.
) Around the Globe
New E-learning Course on
Homotoxicology
Get your certificate now!
By Bruno Van Brandt
T
he International Academy for
Homotoxicology (IAH) provides high-level educational programs and materials on homo­
toxicology and promotes the
ho­mo­toxi­cological model in daily
practice. The IAH has recently introduced an abbreviated course on
the basics of homotoxicology, available as an e-learning program. Enrolment, study, and certification are
free of charge.
IAH educational material is written
by the world’s leading experts in
homotoxicology. It is regularly updated and monitored for scientific
accuracy. The IAH abbreviated online course is the fastest way to get
up to speed on antihomotoxic therapy. The course centers around detailed discussion of approximately
1000 illustrated slides on 20 main
topics in homotoxicology. The high­
ly instructive and well-illustrated
handouts are downloadable and
printable from the internet website.
Th0
E
DH
A
Co
rt
iso
l
How it works
Access the IAH website at www.iahonline.com and register. Once you
have logged in, select “The IAH Abbreviated Course” and then “Lec­tu­res to study” to view the e-learning curriculum. By clicking on the
individual lectures, you can open
the PDF files and either study the
material on screen or print the lectures to make your own textbook.
Successfully completing an online
multiple-choice examination at the
end of the course leads to IAH certification. Just select “Examination”
and follow the instructions. After
passing the exam, you will receive
your certificate by mail within a few
weeks.
Everything on the IAH website is
functionally related to the course of
study. There are no distractions or
disruptions, no commercial pop-ups
or extraneous links competing for
your attention. Once on the website,
you can concentrate on learning the
basics of antihomotoxic treatment.
The many advantages of this IAH
abbreviated internet course include:
After passing the
exam, students will receive a certificate.
• Studying when and where
you want, at your own pace
• Absolutely no charge for
the program
• Course presented in clear,
succinct language
• Material regularly updated
and monitored for scientific
accuracy
• Practical tips for therapy
and follow-up
• Convenient online
multiple-choice examination
• Certification by the IAH,
the only worldwide academy for
homotoxicological education
The IAH abbreviated online course
is open to medical doctors and li­
censed healthcare professionals.|
Th3
Th2
Th1
IL-4, 13
IL-2
IFN-gamma
TGF-beta
IL-5
IL-10
TNF
Inhibition
Inflammation
Allergy
Page taken
from the lecture
“Immunomodulation”
© IAH 2007
by
of hormones
ed the mother
tly DHEA) is call
many other
(and subsequen
to manufacture
Pregnenolone
many body
d by the body
for
use
ary
is
it
ess
e
nec
aus
researchers bec g our sex hormones that are ne, cortisol, etc.). They are
udin
gestero
and mineral
hormones, incl
osterone, pro
s such as fat
., estrogen, test
y body function
racteristics, and
functions (e.g
ntenance of man
mai
and female cha
e
the
mal
for
e other
responsible
ss, maintaining
demand to thes
stre
on
it
s
ing
troll
vert
con
metabolism, con
EA and then
y produces DH
in the
others. The bod
ns
ctio
iated rea
g of Th-1 med
hormones.
e on the long
unity or skewin
but will stimulat
es cellular imm
Th-1 reactions,
retion of cortisol
DHEA stimulat
sec
bits
m
inhi
-ter
isol
that a long
reas cort
balance, whe
nce, inducing
We can state
iated reactions. g at the Th-2 side of the bala auto-immune
term Th-2 med
win
cer. Some
will induce a ske
and even can
(e.g., stress)
une diseases,
-imm
auto
.
e
hn)
allergies, som
the
., morbus Cro
both sides of
Th-1 driven (e.g
in
TGF-β, inhibit
diseases are
dysbalance but
the release of
or cells, over
intervene in the
As Th-3 regulat ulation), it does not directly
reg
ion.
and
balance (down
β
or Th-2 express
1
IL-1
Thof
n
the
both
bits the secretio
el S
the intensity of
1
Traumeel S inhi
is why Traume
duction. That
research that
bit cortisol pro
We know from
ng others.
mediators inhi
F-α. These two
flammation, amo
Curriculum of the
IAH abbreviated
course in homotoxicology
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
)
15
) Re f r e s h Yo u r H o m o t ox i c o l o g y
Synergy Between Functiotropic
and Organotropic Therapy
By Alta A. Smit, MD
The three fundamental pillars of antihomotoxic medicine –
detoxification and drainage, immunomodulation, and organ
support – are implemented to optimize restoration of equili­
brium. Homotoxicology sees the body’s attempts to maintain
homeostasis as symptoms and the extent to which regulation is
possible or not possible as disease.
T
)
16
he Disease Evolution Table
classifies the progression of disease. In simple terms, the regulation/compensation (R/C) division
separates phases in which the patient is still able to regulate towards
health from phases in which only
compensation is possible. Applying
the pillars can assist the patient’s attempts at regulation.
To the left of the R/C division, we
are dealing primarily with disturbances in function; to the right, disturbances in both function and
structure are present. This distinction is less clear in the impregnation
phase (where cell death may be visible only on the microscopic level)
than in the degeneration and dedifferentiation phases (where structural
disturbances generally become macroscopic).
Clearly, therefore, diseases that involve only functional disturbances
will require a different approach
than diseases involving disturbances
in structure as well as function. During the excretion, inflammation, and
deposition phases, regulation still
takes place via excretory mechanisms, so physiological support will
reactivate the organism’s self-regulation. However, once the condition
has progressed to the right of the
R/C division, healing cannot be
achieved without structural support
for specific organs.
Classification of
antihomotoxic medicines:
organotropic vs. functiotropic
Organotropic medications act on a
specific organic system or tissue,
whereas functiotropic medications
ha­ve biochemical and metabolic effects on several organ systems.
Among antihomo­toxic
medicines, the ac­tion of the homaccords and many of the basic combination medications is functiotropic,
whereas the composita and catalysts
act organotropically.
Each pillar, therefore, presents both
functiotropic and organotropic therapeutic options. Taking the detoxification and drainage pillar as our first
example, the Detox-Kit contains
two homaccords – Berberis-Hom­
accord, with functiotropic effects on
the kidneys, and Nux vomica-Hom­
accord, with functiotropic effects on
the intestines and liver – along with
one basic combination (Lymphomyo­
sot, which acts on the lungs, liver,
matrix, and kidneys).
A homaccord is a combination of
two or three single-ingredient potency chords with identical potencies. As with most antihomotoxic
medicines, the action of homaccords
is both synergistic and complementary. Much has been written about
the choice of potencies in the accords. Dr. Reckeweg was also a musician, and many scholars believe
there are similarities between some
) Re f r e s h Yo u r H o m o t ox i c o l o g y
Functiotropic
Organotropic
Basic combinations
Composita
Homaccords
Injeels
(e.g., Hepeel)
(e.g., Hepar compositum)
(e.g., Nux vomica-Homaccord)
(e.g., Hepar suis-Injeel)
Fig. 1: Organ strengthening of the liver
of the accords and chords in music.1-3
There are also mathematical models
that explain the choice of dilutions
in the homaccords. In any case, there
is no doubt that the homaccords are
an essential part of antihomotoxic
treatment. In the Detox-Kit, they effectively deal with mild to moderate
toxicity in all diseases to the left of
the R/C division. In more serious
illnesses, the homaccords (like the
basic combinations) serve to restart
regulation and are generally administered after a period of organ support.
Basic combinations are the other
component of functiotropic treatment. Here, too, the combination of
synergistic and complementary effects induces physiologic regulation.
Traumeel and Lymphomyosot are
two of the most well-known combinations.
There is a long history of therapeutic use of organ extracts in homeopathy. In homotoxicology, the
work of August Bier is thought to
have influenced Reckeweg to include them in the antihomotoxic
repertoire. In his work on treating
chronic disease, Bier had noticed
that organ extracts are more effective than secretory products of the
same organs and concluded that
treating disease in a specific organ
requires a prepared extract of that
organ. Through their work in the
Charité clinic in Berlin, Bier and
Reckeweg were able to demonstrate
empirically that organ therapy is a
superior form of treatment for
chronic disease.
Now scientific evidence is emerging
to support the idea of “resonance”
between organ extracts and their
corresponding organs. Today, fetal
human liver cells and liver extracts
are being used for liver regeneration.4 If therapy with extracts of a
particular tissue has regenerative effects on that tissue, the same should
hold true of the organotropic suisorgan preparations in antihomotoxic
medicines.
Composita and suis-organ Injeels
are examples of medications containing organ extracts. The importance of Reckeweg’s formulations,
however, lies in the fact that he recognized the interdependence among
different organ systems, as mentioned above. Thus the formula of
Cutis compositum includes liver and
adrenal extracts, recognizing the relationships between the skin and
stress hormones and between the
P450 detoxification enzymes in the
skin and the liver. Of course the inclusion of liver and adrenal extracts
also counteracts iatrogenic damage
from products used in skin disease.
On the right side of the R/C division, use of catalysts as well as composita becomes mandatory. Because
no cell can function without energy,
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
the role of catalysts in maintaining
cell health is increasingly being re­
cognized, along with their therapeutic possibilities. For this reason,
advanced organ support protocols
include catalysts in addition to a
number of composita containing
suis organ extracts.
Conclusion
Functiotropic and organotropic me­
dications are administered either
singly or in combination, depending
on the severity of the disease process. An example is basic detoxification and drainage and advanced
organ support in the liver, which
can be depicted as shown in Fi­gure 1.|
References:
1. Milani L. Re-Homaccord® nudo: analisi cri­
tica sugli accordi di potenza e potenze accor­
date. Medicina Biologica 2005;23(4): 45-51.
2. Cahis M. Exact homoeopathy. In: Transactions of the Eighth Quinquennial Homoeopathic
International Congress. Vol 2. London: Publisher unknown;1911:125-147.
3. Cahis M, Kubasta, Kubasta S. Die Homöopathie experimentell bewiesen. Berliner homöopathische Zeitschrift 1913;(4):1-12.
4. Ochenashko OV, Nikitchenko YV, Volkova
NA, Mazur SP, Somov AY, Fuller BJ, Petrenko AY. Functional hepatic recovery after xenotransplantation of cryopreserved fetal liver
cells or soluble cell-factor administration in a
cirrhotic rat model: Are viable cells necessary
[published online ahead of print August 27,
2007]? J Gastroenterol Hepatol. PMID:
17725601.
)
17
) M a r k e t i n g Yo u r P r a c t i c e
Marketing to Target Groups
Are You Getting the Patients You Deserve?
By Marc Deschler
Marketing specialist
“You can’t determine who comes to your practice,” said a
therapist I met with recently. I countered with questions:
Would seniors feel comfortable with designer furniture?
How long would self-employed patients be willing to
wait? Eventually, he admitted that deliberate measures
actually can influence a practice’s clientele.
I
t is no secret anymore that patients
want to be known by name and
given friendly service and personal
care. However, all of this simply ensures that you will get patients; it does
nothing to steer specific types of patients in your direction. If you want
to define a specific target group for
your practice, you need to ask yourself two questions:
1. Who are my current
patients?
2. Who are the patients
I want to treat?
Statistics on office visits alone tell
you precious little – only whether
you are seeing more patients or fewer than before. Your patient database
or Rolodex ought to supply basic
answers to question 1.
)
18
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
What information
do you need?
1. What is the age distribution
of my patients?
Five-year increments are a practical
way of grouping your patients by
age: How many of your patients are
ages 1-5, 6-10, etc.? Heavily represented age groups will be readily
apparent. It is also useful to compare
this information to data on your
community as a whole so you can
tell whether the age distribution in
your practice is typical of your area.
Community-wide data should be
available from local authorities.
2. What is the gender break­
down?
3. What is the distribution of
privately or publicly ensured
and self-paying patients,
po­licy­holders and family
members, working patients
and retirees/seniors?
4. Where do my patients
come from?
Creating a table of postal codes will
allow you to estimate your catchment area.
) M a r k e t i n g Yo u r P r a c t i c e
How well do you know your clientele?
A patient questionnaire will tell you who
your patients are and what they expect
from you.
5. Why do patients come to
my practice?
A patient questionnaire is a quick
and easy way to answer this question. (After making modifications,
use a second questionnaire to assess
the success of your efforts.)
6. When and how often do
patients come to my practice?
Knowing the frequency and timing
of office visits of each of these patient groups will help you schedule
your office hours more effectively.
After you have identified your current clientele, the next step is to decide on your future target group.
That is easy for businesses that sell
products – they simply drop certain
sales areas or step up their advertising on the basis of which groups
buy the most. In a healthcare practice, however, you will want to consider whom you want to serve and
can treat most effectively.
Steps to take
1. Define your goals.
These goals need to be quantifiable,
realistic, and specific. To accomplish
the goal of having more patients
who pay out-of-pocket, all you need
to do is treat 51 such patients this
year in comparison to 50 last year.
Make your goal specific: In the next
two quarters, I will see 40 new patients in the 30-40 year age range.
2. Identify problems experi­
enced by your target group.
Unless you know what your target
group is looking for, you cannot offer solutions. For example, are you
targeting working people who value
short waiting times?
3. Develop solutions.
What will the solutions look like?
Brainstorm with your assistants or
seek advice outside your practice.
Possible solutions might include offering evening and weekend office
hours or guaranteed appointment
times; improving the parking situation, changing the services you offer, changing the ambiance in your
office, etc.
4. Implement solutions.
The best solutions amount to nothing without meticulous planning
and implementation. Do you need
to have a team meeting about scheduling changes? Optimize your appointment planning, talk to your
landlord, take a continuing educa-
tion course, or improve the signage
in your office? Make sure everyone
on your staff knows who needs to
do what and when.
Conclusion
Getting the patients you want requires discipline, strategizing, and
in-depth information about your
current patients. Current data can
also help you identify deviations
from your target state and respond
quickly. Specializing in a particular
target group will have positive effects not only on your job satisfaction but also on your ability to survive in the marketplace. The
internationally known marketing
expert Edgar K. Geffroy once said
something to the effect that lasting
security is achieved only through
customers in the form of target
groups. You will not have to worry
about growing your practice as long
as you specialize in one target group
and constantly keep its needs in
mind. It is true that most practitioners do not need to be concerned
about growth, but good target marketing also increases patient loyalty
and ensures a steady income due to
returning patients.|
To define a specific target group,
health care practitioners need to
decide which patients they want
to treat.
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
)
19
) Specialized Applications
Detoxification of Patients
in the Dedifferentiation Phase
By Kristy Anderson, ND
Toxins and cancer are closely related. A number of environ­
mental toxins contribute to the development of cancer and may
do so even in minute doses through the process of hormesis.1
Toxins may affect the DNA itself and act as genotoxins, or
they may function as adjuvants to the development of certain
cancers in genetically susceptible individuals.2,3
C
ancer therapies themselves are
toxic and harmful to healthy
cells as well as diseased cells. Anti­
neoplastic agents are useful in treating tumors but have several side effects and may accumulate in the
tissues, increasing the toxic burden.
There is also clear evidence that
some antineoplastic drugs are themselves carcinogenic.4
)
20
Special precautions in cancer
patients
As a general rule, patients undergoing active chemotherapy should be
put on only the advanced organ support phase of detoxification, not on
the drainage part with Lymphomyosot, because the concentration of
chemotherapy drugs needs to be
maintained for as long as possible
for full effectiveness (see protocol in
Table 1).
Unless they are in true long-term remission, patients with soft tumors
such as lymphoma and leukemia
should not undergo drainage with
Lymphomyosot and Galium-Heel at
all. Increased lymph drainage may
spread the tumor.
Severely debilitated patients or patients who are in remission or post
chemo but still weakened should
not undergo aggressive detoxification and drainage.
Special care is also needed in patients with hormone-dependent
can­cers such as breast or prostate
can­cer, which may respond to endocrine-disrupting toxins (e.g., organochlorines) released from the matrix.
Detoxification and especially drainage should be extremely gradual in
these patients. They often benefit
from a longer period of advanced
organ support (12 weeks) and from
administering the components of
the Detox-Kit in succession rather
than simultaneously: Nux vomicaHomaccord first, followed by Berberis-Homaccord and finally Lymphomyosot. (For the general protocol
and rationale for advanced organ
support vs. basic detoxification, see
BT Spring 2007.)
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
With these considerations in mind,
we can separate patients into groups
with different detoxification needs:
1. Healthy patients
at high risk for cancer
In such cases, treatment is prophylactic and can often be quite aggressive. However, for patients in one of
the high-risk groups (including
obese patients or those with known
high toxin exposure) advanced organ support must be administered
first, as described in Table 1.
Detoxification and drainage should
be performed at least twice a year
for three years, especially if the patient is non-reactive. (Non-reactive
patients are often not susceptible to
acute feverish illnesses but are susceptible to deep viral recurrences,
such as Epstein-Barr and zoster. This
is a sign of Th2 rigidity and is therefore indicative of a low cellular immunity, which is a risk factor in cancer.) Extended drainage with
Lymphomyosot (at least 12 weeks
after the basic detoxification and
drainage with the Detox-Kit is completed) is advised. These patients
may experience an episode of acute
feverish illness, which is a good
sign.
2. Patients in remission who
need to detoxify aggressively
This group consists of patients who
have completed cancer therapy and
are officially in remission after subsequent check-ups. Their detoxifica-
) Specialized Applications
tion needs are similar to those of
group 1, but detoxification should
be more gradual, especially as these
patients may have residual kidney
and liver damage from aggressive
chemotherapy. For them, the detoxification and drainage process begins
with an advanced organ support
phase, followed by the basic detoxification and drainage phase. Again,
drainage alone is continued for several weeks after the basic treatment.
3. Able-bodied patients with
seemingly incurable cancers
Here, the aim is to prolong high
quality of life. Antihomotoxic medicine is very well suited to these patients, and they often enjoy a heightened sense of well-being after a
course of treatment. In general, the
Disease-specific treatment
drainage phase is not implemented
in these patients unless they are well
and the tumor is progressing slowly.
Support for cellular respiration is
very important in these cases, as is
advanced organ support, which allows the body to detoxify at its own
pace (for general protocols, see BT
Winter 2007). The organism needs
extra energy to detoxify properly, so
it must be sufficiently vigorous before detoxification and drainage are
initiated. Since the object is to preserve quality of life, aggressive detoxification and drainage should not
be implemented.
4. Cancer patients who
have received chemotherapy
As mentioned earlier, at least six
weeks should elapse between com-
pleting chemotherapy and beginning tissue drainage. See the protocol in Table 1 for treatment during
chemo and support afterwards.|
References:
1. Calabrese EJ, Baldwin LA. Hormesis: Usha­ped dose responses and their centrality in
toxicology. Trends Pharmacol Sci 2001;22(6):
285-291.
2. Armstrong B, Hutchinson E, Unwin J, Fletcher T. Lung cancer risk after exposure to polycyclic aromatic hydrocarbons: A review and
meta-analysis. Environ Health Perspect 2004;
112(9):970-978.
3. Brody JG, Rudel RA. Environmental pollutants and breast cancer. Environ Health Perspect
2003;111(8):1007-1019.
4. Haussmann W. Carcinogenicity of cytostatic
agents – Secondary malignancy after chemotherapy. In: Rüther U, Nunnensiek C, Schmoll
H-J, eds. Secondary Neoplasias Following Chemotherapy, Radiotherapy, and Immunosuppression.
Contrib Oncol. Vol 55. Basel: Karger;
2000:36-61.
1. Select organ system where cancer is present
2. Add Ginseng compositum
Advanced organ support (may be started during chemo)
Liver
Urinary tract/
Kidney
Lymph
Gut
Connective
tissue
Advanced organ support
Hepar comp.
Solidago comp.
Tonsilla comp.
Mucosa comp.
Thyreoidea comp.
Alternative products
(if above not available)
Hepeel
Reneel
Nux vomica-Homaccord
Pulsatilla comp.
For cellular detoxification, add
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Note
The organotropic compositum medications support the organs of detoxification but do not stimulate active drainage. If patients are very ill, do not start them
immediately on Ubichinon comp. Tonsilla comp. must be given by mouth. Cutis compositum (supportive in alopecia) can be added when chemotherapy affects
the skin and hair.
Dosage
Ampoules: In general, 3-1 times weekly 1 ampoule i.m., s.c., i.d.
Drops: In general, 10 drops 3 times daily
Begin six weeks after chemotherapy or as a follow-up to advanced support:
Disease-specific treatment
1. Medication specific to the type of cancer
2. Ginseng compositum
Liver
Urinary tract/
Kidney
Lymph
Gut
Connective
tissue
Basic detoxification and drainage
Detox-Kit
Detox-Kit
Detox-Kit
Detox-Kit
Detox-Kit
For cellular detoxification, add
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Coenzyme comp./
Ubichinon comp.
Note
If patients develop expectoration from the lungs, Bronchalis-Heel can be added. Use with caution in patients with bronchial carcinoma as Bronchalis-Heel will
promote expectoration, and thus mucous flow.
Dosage
Ampoules: In general, 3-1 times weekly 1 ampoule i.m., s.c., i.d.
Drops: In general, 10 drops 3 times daily
Table 1: Protocol for cancer patients after chemotherapy
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
)
21
) Making of ...
Manufacturing Liquid Medications:
How Do Those Drops
Get Into the Bottle?
By Rüdiger Schneider, PhD
No one thinks twice about using liquid medications,
especially drops for detoxification and drainage. I’m sure
you’ve prescribed the Detox-Kit for your patients or perhaps
even used it yourself. But have you ever wondered how those
drops get into the bottle?
I
t all starts with the active ingredients. The mother tinctures are inspected before they are introduced
into the manufacturing process. The
German Homeopathic Pharmacopoeia (HAB), the basis for all production of homeopathic medications, dictates exactly which lab
parameters must be tested. Heel’s internal rules require additional tes­­t­
ing to ensure that production meets
GMP standards, so tests for microbiological purity are always performed in addition to tests for physical properties.
Each liquid product has its own
sheet of production instructions
with a bill of material detailing exact quantities of the various components.
After the mother tinctures pass in­
spec­tion, the next step is making
single-ingredient dilutions. A number of these dilutions are then combined into a “potency mixture” and
potentized together by adding a
precisely specified amount of an
ethanol/water blend. The potentized mixtures are then combined to
produce the finished product.
A variety of active ingredients, usually
in the form of mother tinctures or
single potencies, are used in manufac-
)
turing homeopathic drops. Exact
quantities are given in the manufactur-
22
ing instructions, which are specific to
each medication.
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
Every step of
production is
carefully monitored
and precisely
documented.
Alternatively, single-ingredient dilutions may be potentized directly
with the ethanol/water blend to
create the finished product. Whether
potency mixtures or individual potencies are used is precisely defined
by the HAB and depends on which
raw materials or mother tinctures are
involved. To prevent mix-ups when
weighing out single-ingredient dilutions, each dilution is labeled not
only with its classical homeopathic
description but also with a bar code
that includes the batch number and
material number.
Before the newly completed finished product is packaged, it undergoes another series of tests for physical and microbiological properties,
including pH, Hazen number, density, and TLC (thin-layer chromatography). The product is cleared
for packaging only when all of the
test results are satisfactory.
Automated recording of all individual steps in the process allows the
origins of each batch to be traced at
One of the active ingredients of
Lymphomyosot drops: Juglans regia,
better known as walnut. Equal parts
of the fresh leaves and the fresh rind
of the green fruit are used to produce
the mother tincture.
any time. Clearance to proceed to
the next step is also issued automatically. In addition, in-process monitoring ensures correct completion of
individual production stages and intermediate stages even in complex
production runs involving large
numbers of ingredients.
All workstations involved in either
manufacturing or packaging the finished product are doubly inspected
before being cleared for use. (Since
four eyes are better than two, two
employees complete the same checklist.)
Before the finished product is packaged, the filling equipment is first
cleaned and rinsed. Depending on
the fill quantity (30 or 100 ml), the
bottling machines can fill either four
or six bottles simultaneously. Each
assembly line can process approximately 4,000 units per hour, depending on the fill volume. The filling operation is followed by an
initial automated inspection of fill
levels.
Next the tamper evident bottle caps
are screwed on and tightened to a
predetermined torque; labels (which
already include the batch number
and expiration date) are then applied. To avoid mix-ups and ensure
automatic rejection of any incorrect
or damaged packaging, all labels,
package inserts, and boxes are
marked with bar codes that are read
by a scanner.
Journal of Biomedical Therapy 2007 ) Vol. 1, No. 2
Filling, labeling, and packing
the bottles are fully automated
processes. Of course they are also
monitored constantly.
At this point, the process is nearing
completion. The bottles (along with
package inserts) are boxed, and the
expiration date and batch number
are printed on the boxes, which are
checked again for completeness before each unit is sealed.
A belt weigher at the end of the production line rechecks the fill level
and rejects any underfilled bottles.
After banding, the new batches are
then ready for shipping.
The process of manufacturing liquid
homeopathic medications is highly
complex and requires a correspondingly high degree of documentation. Every step of the way is monitored, and the documentation is
constantly checked by the team
leader and the production manager.
The end result? Those familiar bot­
tles of drops, which are easy to use
and ensure accurate dosing. The
best-known example is the DetoxKit, which includes three liquid
medications – Lymphomyosot, Nux
vomica-Homaccord, and BerberisHomaccord – for detoxification and
drainage. The Detox-Kit is becoming increasingly popular worldwide,
but that’s hardly surprising, is
it?|
)
23
) Crossword Puzzle
Solve the puzzle and win!
Here’s how it works: Complete the
crossword puzzle and enter the letters from the numbered boxes in the
blanks to make a word. Then e-mail
your solution to:
[email protected] to enter it
in our drawing before March 15,
2008. Ten lucky winners will receive copies of the book “Biological
Medicine in Pediatrics” (Ulrich
Wemmer, ed.). Please remember to
include your complete mailing address. Results of the drawing are
final. Good luck!
Solution to last issue’s puzzle:
T r au meel